Kennedy Disease

Kennedy Disease, also known as X-linked bulbospinal muscular atrophy, is a progressive neuromuscular disorder caused by mutations in the androgen receptor gene and characterized by wasting of proximal and bulbar muscles. Follow the research into Kennedy Disease with this feed.

February 9, 2021
Open Access

Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy.

Frontiers in Neurology
Elina MillereViktorija Kenina
December 16, 2020
Open Access

SQSTM1L341V variant that is linked to sporadic ALS exhibits impaired association with MAP1LC3 in cultured cells

Masahisa NozakiShinji Hadano
December 6, 2020

A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases

Chemical Biology & Drug Design
Hang HuDefeng Xu
November 22, 2020

Disorders of sleep in spinal and bulbar muscular atrophy (Kennedy's disease)

Sleep & Breathing = Schlaf & Atmung
Lisa LangenbruchMatthias Boentert
November 14, 2020
Open Access

The prevalence of hereditary neuromuscular disorders in Northern Norway.

Brain and Behavior
Kai Ivar MüllerKjell Arne Arntzen
November 11, 2020
Open Access

Deubiquitinase USP7 contributes to the pathogenicity of spinal and bulbar muscular atrophy

The Journal of Clinical Investigation
Anna PluciennikDiane E Merry
October 28, 2020
Open Access

Genotype and Clinical Phenotype Analysis of a Family of Kennedy Disease

CAI benchiTao Chen
September 17, 2020

Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy

Journal of Neurology, Neurosurgery, and Psychiatry
Kazumoto ShibuyaSatoshi Kuwabara
September 17, 2020

Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA)

Journal of Neurology, Neurosurgery, and Psychiatry
Atsushi HashizumeMasahisa Katsuno
August 29, 2020

ClC-2-like Chloride Current Alterations in a Cell Model of Spinal and Bulbar Muscular Atrophy, a Polyglutamine Disease.

Journal of Molecular Neuroscience : MN
Vladimir A Martínez-RojasCarlo Musio
August 28, 2020

Harmony Lost: Cell-Cell Communication at the Neuromuscular Junction in Motor Neuron Disease

Trends in Neurosciences
Anastasia Gromova, Albert R La Spada
August 26, 2020

Kennedy's disease: an under-recognized motor neuron disorder

Acta neurologica Belgica
Elia G MalekAchraf Makki
August 15, 2020
Open Access

A Crucial Role for the Protein Quality Control System in Motor Neuron Diseases

Frontiers in Aging Neuroscience
Riccardo CristofaniAngelo Poletti
August 11, 2020

Molecular pathogenesis of spinal bulbar muscular atrophy (Kennedy's disease) and avenues for treatment

Current Opinion in Neurology
Christopher Grunseich, Kenneth H Fischbeck
July 31, 2020

Myoglobin: A new biomarker for spinal and bulbar muscular atrophy?

The International Journal of Neuroscience
Haixiao GuoXiaolu Liu
July 23, 2020
Case Report
Open Access

Bulbospinal muscular atrophy (Kennedy disease) responsive to immunoglobulins?

Clinical Case Reports
Katharina PoustkaJosef Finsterer

Sign up to follow this feed and discover related papers.

Related Feeds

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused as a result of a partial deletion of chromosome 22. Here is the latest research.

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

4H Leukodystrophy

4H Lekodystrophy involves hypomyelination, hypogonadotropic hypogonadism and hypodontia. It is also known as POLR-3Related Leukodystrophy. 4H syndrome symptoms include delayed or abnormal puberty, issues with central nervous system signal transmission, abnormal development of teeth, and symptoms tend to progressively get worse over time. There is not yet a known cure.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

© 2021 Meta ULC. All rights reserved